<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-22T07:57:45Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/D009C30C-B968-4166-945F-F50CCB54B277" ns1:id="D009C30C-B968-4166-945F-F50CCB54B277"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/A265ADA3-9825-48D3-A75E-9EEB4B0658B7" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/02AD33BE-EA22-4783-91C7-3A4FAA29336B" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/964A73A3-66DC-4C55-AB50-59AE3100C18E" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/C4C0DE24-F913-4D69-BB8B-B4146645D03D" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/D58F432A-C311-4BF0-B865-62DE5CD56482" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/F2E84E6E-D7EB-44C9-BE7F-B89A1B1EDA9C" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/02AD33BE-EA22-4783-91C7-3A4FAA29336B" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/460210B6-F150-43BB-93E4-91D9E9F91AC6" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2026-03-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/ED2C9E19-08C5-45F5-91E5-A5AF88785AA8" ns1:rel="FUND" ns1:start="2025-03-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10157761</ns2:identifier></ns2:identifiers><ns2:title>GM Advanced Diagnostics Accelerator (ADA) - Extension</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Investment Accelerator</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>The understanding of disease mechanisms is advancing rapidly, leading to innovations which enable earlier and more accurate detection, diagnosis and prognostication, including ruling-out disease in those who can be safely reassured. This gives opportunities for better population health and targeted care pathways bespoke to individuals. However, there remains a critical gap between these discoveries being made in universities or businesses and implementation to local population benefit. An intervention is required to simultaneously tackle health and wealth through inclusive, innovation-led growth.

The Advanced Diagnostics Accelerator - extension will continue to do this through a series of projects looking at GM's major morbidities (liver, heart, lung, CVD) in which academic and industry excellence from our frontier sectors of advanced diagnostics and digital/data will be brought together to reimagine citizen pathways with NHS stakeholders and residents.</ns2:abstractText></ns2:project>